William Dahut

1.1k total citations
19 papers, 887 citations indexed

About

William Dahut is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, William Dahut has authored 19 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in William Dahut's work include Prostate Cancer Treatment and Research (6 papers), Cancer Treatment and Pharmacology (4 papers) and Immunotherapy and Immune Responses (4 papers). William Dahut is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Cancer Treatment and Pharmacology (4 papers) and Immunotherapy and Immune Responses (4 papers). William Dahut collaborates with scholars based in United States and Argentina. William Dahut's co-authors include Michael Hawkins, Erwin A. Kruger, John L. Marshall, Naiyer A. Rizvi, Pankaj Bhargava, Douglas K. Price, William D. Figg, S. M. Steinberg, James M. Pluda and Clara C. Chen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

William Dahut

19 papers receiving 864 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Dahut United States 11 464 323 287 190 119 19 887
Michael A. Levesque Canada 19 405 0.9× 407 1.3× 336 1.2× 220 1.2× 98 0.8× 32 1.2k
Sujatha Jagadeeswaran United States 12 465 1.0× 360 1.1× 169 0.6× 197 1.0× 50 0.4× 16 973
Borys Korchin United States 13 614 1.3× 235 0.7× 188 0.7× 412 2.2× 145 1.2× 18 1.1k
Christopher Ruel United States 18 468 1.0× 536 1.7× 309 1.1× 131 0.7× 93 0.8× 47 1.0k
Erwan Pencreach France 17 323 0.7× 350 1.1× 200 0.7× 248 1.3× 58 0.5× 35 797
Carla Kurkjian United States 17 481 1.0× 302 0.9× 157 0.5× 130 0.7× 41 0.3× 41 830
Jay Yang United States 18 810 1.7× 281 0.9× 205 0.7× 156 0.8× 318 2.7× 103 1.3k
Philipp Manegold United States 14 404 0.9× 446 1.4× 124 0.4× 147 0.8× 51 0.4× 23 919
D. J. Th. Wagener Netherlands 18 311 0.7× 506 1.6× 401 1.4× 154 0.8× 48 0.4× 57 1.1k
Wenhua Lang United States 17 784 1.7× 374 1.2× 304 1.1× 257 1.4× 33 0.3× 28 1.3k

Countries citing papers authored by William Dahut

Since Specialization
Citations

This map shows the geographic impact of William Dahut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Dahut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Dahut more than expected).

Fields of papers citing papers by William Dahut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Dahut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Dahut. The network helps show where William Dahut may publish in the future.

Co-authorship network of co-authors of William Dahut

This figure shows the co-authorship network connecting the top 25 collaborators of William Dahut. A scholar is included among the top collaborators of William Dahut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Dahut. William Dahut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Madan, Ravi A., Renee N. Donahue, Fatima Karzai, et al.. (2022). 1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1191–S1191. 1 indexed citations
2.
Kamrava, Mitchell, Aparna H. Kesarwala, Ravi A. Madan, et al.. (2012). Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer and Prostatic Diseases. 15(3). 289–295. 10 indexed citations
3.
Wood, Lauren V., William Dahut, James L. Gulley, et al.. (2011). Abstract 5520: Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage D0 prostate cancer. Cancer Research. 71(8_Supplement). 5520–5520. 1 indexed citations
4.
Porter‐Gill, Patricia, Yi‐Ping Fu, Douglas K. Price, et al.. (2011). Detection of bladder, breast and prostate cancer using serum and tissue miRNA profiling. Genome biology. 12(S1). 28 indexed citations
5.
Sissung, Tristan M., Caitlin E. Baum, John F. Deeken, et al.. (2008). ABCB1 genetic variation influences the toxicity and clinical outcome of patients treated with docetaxel. Cancer Research. 68. 4781–4781. 1 indexed citations
6.
7.
Takimoto, Chris H., Scot C. Remick, Sunil Sharma, et al.. (2003). Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study. Journal of Clinical Oncology. 21(14). 2664–2672. 95 indexed citations
8.
Gulley, James L. & William Dahut. (2002). Novel Clinical Trials in Androgen-Independent Prostate Cancer. PubMed. 1(1). 51–57. 9 indexed citations
9.
Figg, William D., Erwin A. Kruger, Douglas K. Price, Sonia Kim, & William Dahut. (2002). Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer. Investigational New Drugs. 20(2). 183–194. 72 indexed citations
10.
Figg, W D, William Dahut, Paul H. Duray, et al.. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.. PubMed. 7(7). 1888–93. 243 indexed citations
11.
Bhargava, Pankaj, John L. Marshall, Karen Fried, et al.. (2001). Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 48(2). 95–103. 29 indexed citations
12.
Bhargava, Pankaj, J L Marshall, William Dahut, et al.. (2001). A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.. PubMed. 7(12). 3912–9. 63 indexed citations
13.
Chen, Helen X, John L. Marshall, Elizabeth Ness, et al.. (2000). A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.. PubMed. 6(4). 1259–66. 52 indexed citations
14.
Bhargava, Pankaj, John L. Marshall, Naiyer A. Rizvi, et al.. (1999). A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.. PubMed. 5(8). 1989–95. 120 indexed citations
15.
Rizvi, Naiyer A., John L. Marshall, William Dahut, et al.. (1999). A Phase I study of LGD1069 in adults with advanced cancer.. PubMed. 5(7). 1658–64. 88 indexed citations
16.
Grem, Jean L., Pedro M. Politi, Stacey L. Berg, et al.. (1996). Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochemical Pharmacology. 51(12). 1649–1659. 23 indexed citations
17.
Monahan, Brian P., et al.. (1996). Clinical aspects of expression of inversion 16 chromosomal fusion transcript CBFB/MYH11 in acute myelogenous leukemia subtype M1 with abnormal bone marrow eosinophilia.. PubMed. 10(10). 1653–4. 4 indexed citations
18.
Politi, Pedro M., William Dahut, Harry Ford, et al.. (1995). Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology. 36(6). 513–523. 37 indexed citations
19.
Politi, Pedro M., William Dahut, Harry Ford, et al.. (1995). Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology. 36(6). 513–523. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Levesque Breakdown of academic impact, for papers by Sujatha Jagadeeswaran Breakdown of academic impact, for papers by Borys Korchin Breakdown of academic impact, for papers by Christopher Ruel Breakdown of academic impact, for papers by Erwan Pencreach Breakdown of academic impact, for papers by Carla Kurkjian Breakdown of academic impact, for papers by Jay Yang Breakdown of academic impact, for papers by Philipp Manegold Breakdown of academic impact, for papers by D. J. Th. Wagener Breakdown of academic impact, for papers by Wenhua Lang
Rankless by CCL
2026